BMI guidelines for bariatric surgery in diabetes: How low can we go?

Diabetes Care

Volumn 35, Issue 7, 2012, Pages 1399-1400

  Ryan, Donna H ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; PANCREAS ISLET CELL ANTIBODY;

BARIATRIC SURGERY; BODY MASS; BRAZIL; CARDIOVASCULAR RISK; CELL FUNCTION; DIABETES CONTROL; DIABETES MELLITUS; DISEASE SEVERITY; FOLLOW UP; GLYCEMIC CONTROL; HEMATOMA; HUMAN; JEJUNUM ULCER; LAPAROSCOPY; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; POPULATION RESEARCH; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; REFERENCE VALUE; REMISSION; RISK BENEFIT ANALYSIS; RISK FACTOR; ROUX Y ANASTOMOSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEIGHT CONTROL; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC BYPASS; HUMANS; MALE;

EID: 84862895345     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0729     Document Type: Note

References (12)

1. Wing RR; Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170:1566-1575
2. Pi-Sunyer X, Blackburn G, Brancati FL, et al.; Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30:1374-1383 (Pubitemid 46871141)
3. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review andmeta-analysis. Am J Med 2009;122:248-256, e5
4. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care 2009;32:2133-2135
5. Pournaras DJ, Aasheim ET, Søvik TT, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg 2012;99:100-103
6. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998;6(Suppl. 2):51S-209S
7. Cohen RV, Pinheiro JC, Schiavon CA, Salles JE,Wajchemberg B, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012;35:1420-1428
8. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-1576
9. Cummings DE, Overduin J, Shannon MH, Foster-Schubert KE; 2004 ABS Consensus Conference.Hormonalmechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat Dis 2005;1:358-368
10. Korner J, Bessler M, InabnetW, Taveras C, Holst JJ. Exaggerated glucagon-like peptide- 1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007;3:597-601 (Pubitemid 350091417)
11. Flum DR, Belle SH, King WC, et al.; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009;361:445-454
12. Sjöström L, Lindroos AK, Peltonen M, et al.; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693 (Pubitemid 39665322)